Impurities test for Trimethoprim (EP-8.0 method) - For Impurities-E, D, G, B, J and F

Importance of the Topic

Trimethoprim is a widely used antibacterial agent. Monitoring its purity and identifying related impurities is crucial for ensuring drug safety, therapeutic efficacy, and regulatory compliance. An established European Pharmacopoeia (EP-8.0) analytical procedure allows precise quantification of key impurities (E, D, G, B, J, F) in trimethoprim bulk material and finished products.

Objectives and Study Overview

The primary objective is to apply and validate the EP-8.0 chromatographic method for the accurate determination of six specified impurities in trimethoprim. The study examines sample preparation protocols, chromatographic separation, system suitability performance, and quantification capability.

Methodology and Instrumentation

Sample Preparation:

• Test Solution: 25 mg trimethoprim dissolved in mobile phase and diluted to 25 mL.
• Reference Solution (a): 1 mL test solution diluted to 200 mL.
• Reference Solution (b): CRS vial containing impurity‐E dissolved in 1 mL mobile phase.

Chromatographic Conditions and Instrumentation:

• Instrument: UltiMate 3000 LC system.
• Column: Hypersil Gold, 4.6 × 250 mm, 5 µm.
• Mobile Phase: Methanol and 1.4 g/L sodium perchlorate solution (30:70), adjusted to pH 3.6 with phosphoric acid.
• Mode: Isocratic; Flow Rate: 1.3 mL/min; Column Temperature: 25 °C.
• Injection Volume: 20 µL; Detector: UV at 280 nm; Run Time: 40 min.

Main Results and Discussion

System suitability parameters exceeded EP criteria:

• Resolution between trimethoprim and impurity-E: obtained 7.7 (threshold ≥ 2.5).
• Tailing factor for trimethoprim: obtained 1.1 (threshold ≤ 2.0).

The high resolution demonstrates clear peak separation, ensuring accurate quantification of each impurity. The low tailing factor indicates sharp, symmetric peaks amenable to precise integration.

Benefits and Practical Applications

By following this validated EP method, quality control laboratories can reliably monitor trimethoprim impurity levels, support batch release decisions, and meet regulatory specifications. The straightforward sample preparation, robust chromatographic conditions, and minimal run time enhance throughput in routine QC environments.

Future Trends and Applications

Potential advancements include:

• Adoption of ultra-high performance liquid chromatography (UHPLC) for faster separations and reduced solvent consumption.
• Integration of mass spectrometric detection to confirm impurity identities and detect trace-level unknowns.
• Automation of sample handling to further improve precision and laboratory efficiency.

Conclusion

The EP-8.0 method for trimethoprim impurity analysis provides robust, precise, and reliable results. Its strong system suitability performance and clear separation of key impurities make it an ideal choice for pharmaceutical quality control. Continued modernization with UHPLC and MS detection promises further gains in speed and analytical power.